Revefenacin
Sponsors
Mylan Inc., Theravance Biopharma, University of Tennessee Graduate School of Medicine
Conditions
COPD ExacerbationChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease, COPDLow Peak Inspiratory Flow Rate (PIFR)
Phase 3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
CompletedNCT03095456
Start: 2017-03-27End: 2017-11-25Updated: 2022-02-24
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
CompletedNCT03573817
Start: 2018-05-31End: 2018-09-25Updated: 2022-02-24
Phase 4
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
CompletedNCT05165485
Start: 2022-01-07End: 2023-11-20Updated: 2024-12-20
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
Not yet recruitingNCT07721922
Start: 2026-09-01End: 2028-09-01Target: 280Updated: 2026-08-17